История изменений

Как известно, вакцины Файзер и Модерна используют военные технологии

Интересно, а кому и откуда это известно?

Почитай кто заказал и когда: https://www.nature.com/articles/d41586-021-00019-w

In 2012, around the time that Geall and his colleagues described1 the first LNP-encapsulated RNA vaccine, the US Defense Advanced Research Projects Agency (DARPA) began funding groups at Novartis, Pfizer, AstraZeneca, Sanofi Pasteur and elsewhere to work on RNA-encoded vaccines and therapeutics. None of the big-name firms stuck with the technology, however. “They were reticent about taking on any risk with a new regulatory pathway for vaccines, even though the data looked good,” says Dan Wattendorf, a former programme manager at DARPA.

But two smaller firms with ties to the DARPA programme continued to work on the technology. One was CureVac in Tübingen, Germany, which began human testing of a rabies vaccine in 20135. CureVac also has a COVID-19 vaccine in late-stage testing.

The other was Moderna, which built on work funded by DARPA to eventually bring an RNA-based vaccine for a new strain of avian influenza into clinical testing in late 2015. It elicited strong enough immune responses6 that the company moved ahead with human trials of RNA vaccines for cytomegalovirus (a common cause of birth defects), two mosquito-borne viruses (chikungunya and Zika) and three viral causes of respiratory illness in children.

Как известно, вакцины Файзер и Модерна используют военные технологии

Интересно, а кому и откуда это известно?

Почитай кто заказал и когда: https://www.nature.com/articles/d41586-021-00019-w